News

The deal, which triggers an undisclosed upfront payment, includes the discovery and optimisation of new compounds as well as licence agreements for already existing assets developed by Evotec.

The application is based on data from an extensive head-to-head preclinical data package comparing SB2 to the originator, a head-to-head Phase I trial in healthy volunteers, and a

The company claims that SAPHRIS is the only atypical antipsychotic treatment option with a sublingual (under the tongue) formulation. The NDA is based on the results of a

The trial was designed to evaluate the safety and efficacy of BAX 817 in male patients aged 12 to 65 years with hemophilia A or B with inhibitors

The company sold about 28.2 million shares in Africa’s pharmaceutical manufacturer for a price of ZAR372 per share. After completion of the sale, GSK will remain a 6.2%

EContra EZ can be used up to 72 hours after unprotected sex or suspected contraceptive failure, but is said to be more effective the sooner it is taken.

The NDA is based on data from a multi-center, double-blind and placebo-controlled Phase III trial of 402 patients, aged 40 and older, with osteoarthritis of the knee or

The new ADC product candidates will be used by OXIS to treat triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions which are significant unmet medical needs.

In March 2015, Boehringer filed a Paragraph IV lawsuit against Breckenridge in the US District Court for the District of New Jersey, in return Breckenridge filed its Paragraph